e-Profile Login and ID Quick Search
DEA Announces Temporary Scheduling of Three Synthetic Cathinones and Proposed Scheduling of Ezogabine
The administrator of the DEA has issued a final order to temporarily schedule three synthetic cathinones – 4-methyl-Nmethylcathinone (mephedrone), 3,4- methylenedioxy-N-methylcathinone (methylone), and 3,4- methylenedioxypyrovalerone (MDPV) – placing them into Schedule I of the Controlled Substances Act (CSA) effective as of October 21, 2011. DEA has determined that the scheduling of these chemicals is necessary to avoid an imminent hazard to the public safety. “As a result of this order, the full effect of the CSA and its implementing regulations including criminal, civil and administrative penalties, sanctions and regulatory controls of Schedule I substances will be imposed on the manufacture, distribution, possession, importation, and exportation of these,” indicates DEA. The final order (PDF) was published in the October 21, 2011 Federal Register.
DEA has also proposed placing the substance ezogabine, a new chemical substance indicated for the treatment of epileptic conditions in humans that has not been marketed in the United States, into Schedule V of the Controlled Substances Act. DEA explains that “Because of the similarities between ezogabine, pregabalin, and lacosamide, it is very likely that ezogabine will have an abuse potential similar to those Schedule V substances.” Written comments on the proposed scheduling of ezogabine may be submitted to DEA by mail or electronically, following the instructions in the October 21, 2011 Federal Register notice (PDF). Electronic comments must be submitted and written comments must be postmarked on or before November 21, 2011.
